###### Strengths and limitations of this study

-   Cardiovascular risk factors and their medications may modify the response to cardioprotective therapies.

-   This is the first examination of a potential modification by cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning (RIC) as an adjunct to primary percutaneous coronary intervention in a randomised controlled trial.

-   We found no significant difference in the efficacy of RIC in subgroups of cardiovascular risk factors and their medications. However, our analysis indicated a reduced effect of RIC among smokers and an increased effect of RIC in statin users.

-   We used subgroup analysis on a limited sample size.

-   Our post hoc analysis should be considered exploratory and calls for further investigation in large-scale multicentre trials.

Introduction {#s1}
============

Remote ischaemic conditioning (RIC) consists of brief episodes of ischaemia administered distant from the heart to protect against myocardial ischaemia-reperfusion injury.[@R1] The stimulus can be applied in a simple, low-cost manner using cycles of inflation and deflation of a blood pressure cuff placed around the upper arm.[@R2] Despite the consistently positive effect of RIC found in animal studies, results have been ambiguous in the clinical setting of cardiovascular surgery and percutaneous coronary intervention.[@R3] [@R4] Most animal studies have been conducted using young and healthy animals. In the clinical setting, patients are older and often have a variety of comorbidities that may modify the effect of RIC and partially explain the bench-to-bedside discrepancy.[@R5] [@R6]

Increasing evidence from animal studies suggests that the effect of ischaemic conditioning is attenuated by ageing, female gender, cardiovascular risk factors and comorbidities, such as diabetes mellitus, hypertension, left ventricular (LV) hypertrophy and hyperlipidaemia.[@R5] [@R6] In addition, several drugs frequently prescribed to patients with coronary artery disease, including statins, β-blockers and oral antidiabetics, may reduce the efficacy of ischaemic conditioning.[@R5] [@R6]

We previously showed that RIC performed in the prehospital setting before primary percutaneous coronary intervention (pPCI) increases myocardial salvage in patients with ST-elevation myocardial infarction (STEMI).[@R7] The present analysis examined whether cardiovascular risk factors, lipid and glucose levels, and medication use modified the efficacy of RIC in patients with STEMI treated with pPCI.

Methods {#s2}
=======

Patients and study design {#s2a}
-------------------------

This post hoc subgroup analysis included all patients in a single-centre randomised controlled trial, performed in Department of Cardiology, Aarhus University Hospital, Denmark.[@R7] Patient selection and randomisation have been described in detail elsewhere.[@R7] In brief, patients were enrolled in the study from February 2007 to November 2008. Criteria for inclusion were: (1) age ≥18 years, (2) symptom duration of ≤12 h prior to admission and (3) ST-segment elevation ≥0.1 mV in two or more contiguous ECG leads.[@R7] Exclusion criteria were: (1) unconfirmed diagnosis during hospital admission, (2) history of previous myocardial infarction, (3) previous coronary artery bypass grafting (CABG) and (4) chest pain \>12 h before admission.[@R7] RIC was initiated in the ambulance during transport to the interventional centre using intermittent arm ischaemia produced by four cycles of alternating 5 min inflation (200 mm Hg) followed by 5 min deflation of a blood pressure cuff placed around the upper arm.[@R7]

Cardiovascular risk factors, lipid and glucose levels, and medication use {#s2b}
-------------------------------------------------------------------------

### Medical history {#s2b1}

On hospital arrival, information about age, gender, smoking status, height, weight, presence of diabetes mellitus, presence of hypertension and medication use, was entered in an electronic case report form for each patient. This information was obtained by interviewing the patient or relatives and subsequently validated by medical record review.

A 'smoker' was defined as an active smoker at the time of myocardial infarction. A 'non-smoker' was defined as a former smoker or never-smoker. Hypertension was defined as treatment with at least one antihypertensive drug at the time of myocardial infarction, with hypertension as the indication for the prescription. Diabetes mellitus was defined as diet-treated, oral-treated or insulin-treated diabetes mellitus at the time of myocardial infarction.

Treatment with β-blockers; ACE inhibitors; angiotensin II receptor blockers (ARBs); calcium channel blockers; and long-acting nitrates, statins, metformin, glimepiride and insulin, were defined as treatment with the drugs at the time of myocardial infarction.

### Echocardiography {#s2b2}

Echocardiography, performed at a median of 13 h after pPCI, permitted evaluation of LV mass. Echocardiography was performed by two investigators using a commercially available ultrasound system (Vivid 7; GE Healthcare) with a 3.5 MHz phased array transducer (M4S). LV mass was calculated from M-mode measurements using the formula of Devereux and adjusted to body surface area.[@R8] Patients were categorised as having LV hypertrophy when LV mass was at least moderately increased compared with reference range (LV mass ≥109 g/m^2^ for women and ≥132 g/m^2^ for men).[@R8]

### Biochemical variables {#s2b3}

Lipid and glucose values were obtained from the Clinical Laboratory Information System (LABKA).[@R9] A non-fasting blood sample taken on hospital arrival was used to measure glucose (mmol/L). Total cholesterol (mmol/L), low-density lipoprotein (LDL) cholesterol (mmol/L) and glycated haemoglobin (HbA1c; %) were measured using a morning fasting blood sample taken the day after admission. Plasma was used for all biochemical analyses.

Outcome measure {#s2c}
---------------

The primary outcome measure was the myocardial salvage index (MSI), estimated by single-photon emission CT (SPECT). The MSI, which quantifies the salvaged myocardium at risk, was calculated as ((area-at-risk (AAR)−final infarct size)/(AAR)). Before pPCI, ^99m^TC-sestamibi was injected intravenously and AAR was measured by SPECT within 8 h after injection. We used the same method to quantify final infarct size 30 days after pPCI, with SPECT performed 1 h after injection of ^99m^TC-sestamibi.

Trial staff members who collected and analysed the data were blinded to treatment assignment.

Statistics {#s2d}
----------

The subgroup analysis was conducted on patients who met trial criteria and achieved data for MSI (n=139). To examine effect modification, we computed stratum-specific differences in MSI between the RIC and control groups, and tested for interaction. Patients were stratified according to cardiovascular risk factors (age; gender; smoking status; body mass index; and presence/absence of diabetes mellitus, hypertension and LV hypertrophy), lipid and glucose levels (total cholesterol, LDL cholesterol, plasma glucose and HbA1c), and medication use (β-blockers, ACE inhibitors, ARBs, calcium channel blockers and statins). Only a very limited number of patients were on antidiabetic medication and long-acting nitrates, so we did not stratify for these medications. Continuous variables were dichotomised using clinical cut-off values as follows: ≥/\<70 years, ≥/\<25 kg/m^2^ (body mass index), ≥/\<5.0 mmol/L (total cholesterol), ≥/\<3.0 mmol/L (LDL cholesterol), ≥/\<11.1 mmol/L (plasma glucose) and ≥/\<6.5% (HbA1c). Because the MSI did not follow a normal distribution, we used non-parametric quantile regression to calculate stratum-specific medians and stratum-specific median differences (with 95% CIs), and to test for interaction between stratum-specific median differences.[@R10] Non-parametric bootstrapping (1000 replications) computed all CIs and p values. Adjustment for multiple testing was not performed. A p value \<0.05 was considered statistically significant. Statistical analyses were made using STATA software (V.12, Stata Corp, College Station, Texas, USA).

Results {#s3}
=======

The study flow chart is shown in [figure 1](#BMJOPEN2014006923F1){ref-type="fig"}. A total of 333 patients with suspected STEMI were randomly assigned to either RIC as an adjunct to pPCI (n=166) or to standard treatment with pPCI alone (n=167). Eighty-two patients were excluded during hospital admission, because they did not meet the trial criteria (34 with an unconfirmed diagnosis of STEMI, 41 with previous myocardial infarction, 4 with previous CABG and 3 with chest pain \>12 h before admission).

![Study flow chart. Grey boxes represent study population eligible for stratified analysis (n=139). AAR, area-at-risk; ARBs, angiotensin II receptor blockers; FIS, final infarct size; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; MSI, myocardial salvage index; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning; STEMI, ST-elevation myocardial infarction.](bmjopen2014006923f01){#BMJOPEN2014006923F1}

Paired AAR and infarct size evaluations from SPECT, used to calculate the primary outcome measure (MSI), were obtained for 140 patients. One patient was excluded from analysis, because the patient developed a large reinfarction between the first and second SPECT evaluations. This resulted in an unreliable MSI. The remaining 139 patients (71 patients in the RIC group and 68 patients in the control group) were eligible for further analysis.

Cardiovascular risk factors, lipid and glucose levels, and medication use did not differ substantially between the RIC and control groups, except for hypertension, which was more common in the RIC group ([table 1](#BMJOPEN2014006923TB1){ref-type="table"}). Procedural data did not differ between the RIC and control groups and have been published in detail elsewhere.[@R7]

###### 

Cardiovascular risk factors, lipid and glucose levels, and medication use for the study population eligible for stratified analysis

                                    RIC+pPCI (n=71)   pPCI (n=68)
  --------------------------------- ----------------- ----------------
  **Cardiovascular risk factors**                     
  Age (years)                       63 (±11)          62 (±11)
  Male                              57 (80%)          55 (81%)
  Smoker                            34 (48%)          38 (56%)
  Body mass index (kg/m^2^)         26 (±4)           26 (±4)
  Diabetes mellitus                 6 (8%)            8 (12%)
  Hypertension                      32 (45%)          19 (28%)
  Left ventricular hypertrophy      7 (10%)           8 (12%)
  **Lipid and glucose levels**                        
  Total cholesterol (mmol/L)        4.9 (4.1--5.6)    4.7 (3.8--5.4)
  LDL cholesterol (mmol/L)          3.0 (2.3--3.7)    3.0 (2.2--3.6)
  Plasma glucose (mmol/L)           7.7 (6.3--9.9)    8.0 (6.9--9.5)
  HbA1c (%)                         5.9 (5.6--6.1)    5.8 (5.6--6.2)
  **Medication use**                                  
  Metformin                         3 (4%)            3 (4%)
  Glimepiride                       0 (0%)            1 (1%)
  Insulin                           1 (1%)            2 (3%)
  β-blockers                        11 (15%)          10 (15%)
  ACE inhibitors                    14 (20%)          6 (9%)
  ARBs                              10 (14%)          5 (7%)
  Long-acting nitrates              0 (0%)            0 (0%)
  Calcium channel blockers          7 (10%)           8 (12%)
  Statins                           12 (17%)          12 (18%)

Data are presented as mean (SD), median (IQR) or number (%).

ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning.

Information about cardiovascular risk factors and medication use was available for 98--100% of the patients. An exception was LV mass, which was available for only 65% of the patients. Data on lipid and glucose levels were available for 72--85% of the patients (total cholesterol 85%, LDL cholesterol 83%, plasma glucose 75% and HbA1c 72%). There was no difference in availability of these data between the two randomisation groups ([table 2](#BMJOPEN2014006923TB2){ref-type="table"}).

###### 

Stratum-specific medians and median differences in myocardial salvage index between RIC and control groups according to cardiovascular risk factors, lipid and glucose levels, and medication use

                                    RIC+pPCI   pPCI                                                                     
  --------------------------------- ---------- --------------------- ---- --------------------- ----------------------- ------
  Overall population                71         0.75 (0.64 to 0.86)   68   0.56 (0.42 to 0.70)   0.19 (0.01 to 0.37)     0.03
  **Cardiovascular risk factors**                                                                                       
  Age (years)                                                                                                           
   ≥70                              23         0.67 (0.43 to 0.91)   21   0.53 (0.38 to 0.68)   0.14 (−0.14 to 0.42)    0.87
   \<70                             48         0.76 (0.66 to 0.86)   47   0.65 (0.46 to 0.84)   0.11 (−0.11 to 0.33)    
  Gender                                                                                                                
   Female                           14         0.93 (0.70 to 1.00)   13   0.60 (0.37 to 0.83)   0.33 (0.01 to 0.65)     0.56
   Male                             57         0.74 (0.56 to 0.92)   55   0.53 (0.38 to 0.68)   0.21 (−0.03 to 0.45)    
  Smoking status                                                                                                        
   Smoker                           34         0.63 (0.44 to 0.82)   38   0.65 (0.42 to 0.88)   −0.02 (−0.32 to 0.28)   0.13
   Non-smoker                       37         0.80 (0.68 to 0.92)   29   0.55 (0.42 to 0.68)   0.25 (0.08 to 0.42)     
  Body mass index (kg/m^2^)                                                                                             
   ≥25                              44         0.73 (0.56 to 0.90)   41   0.53 (0.37 to 0.69)   0.20 (−0.03 to 0.43)    1.00
   \<25                             27         0.75 (0.60 to 0.90)   25   0.55 (0.34 to 0.76)   0.20 (−0.06 to 0.46)    
  Diabetes mellitus                                                                                                     
   Yes                              6          0.80 (0.62 to 0.98)   8    0.60 (0.36 to 0.84)   0.20 (−0.10 to 0.50)    0.92
   No                               65         0.74 (0.61 to 0.87)   60   0.56 (0.40 to 0.72)   0.18 (−0.02 to 0.38)    
  Hypertension                                                                                                          
   Yes                              32         0.76 (0.65 to 0.87)   19   0.60 (0.37 to 0.83)   0.16 (−0.10 to 0.42)    0.84
   No                               39         0.67 (0.45 to 0.89)   49   0.55 (0.40 to 0.70)   0.12 (−0.15 to 0.39)    
  Left ventricular hypertrophy                                                                                          
   Yes                              7          0.50 (0.30 to 0.70)   8    0.48 (0.23 to 0.73)   0.02 (−0.30 to 0.34)    0.35
   No                               36         0.76 (0.62 to 0.90)   39   0.55 (0.37 to 0.73)   0.21 (−0.02 to 0.44)    
  **Lipid and glucose levels**                                                                                          
  Total cholesterol (mmol/L)                                                                                            
   ≥5.0                             27         0.78 (0.68 to 0.88)   22   0.55 (0.35 to 0.75)   0.23 (0.00 to 0.46)     0.86
   \<5.0                            34         0.76 (0.57 to 0.95)   35   0.50 (0.33 to 0.67)   0.26 (0.01 to 0.51)     
  LDL cholesterol (mmol/L)                                                                                              
   ≥3.0                             30         0.78 (0.67 to 0.89)   29   0.55 (0.40 to 0.70)   0.23 (0.05 to 0.41)     0.72
   \<3.0                            29         0.79 (0.63 to 0.95)   28   0.50 (0.28 to 0.72)   0.29 (0.02 to 0.56)     
  Plasma glucose (mmol/L)                                                                                               
   ≥11.1                            6          0.73 (0.44 to 1.00)   7    0.48 (0.29 to 0.67)   0.25 (−0.09 to 0.59)    0.25
   \<11.1                           46         0.67 (0.50 to 0.84)   45   0.68 (0.51 to 0.85)   0.01 (−0.23 to 0.25)    
  HbA1c (%)                                                                                                             
   ≥6.5                             6          0.80 (0.60 to 1.00)   5    0.48 (0.12 to 0.84)   0.32 (−0.09 to 0.73)    0.73
   \<6.5                            46         0.77 (0.65 to 0.89)   43   0.53 (0.39 to 0.67)   0.24 (0.06 to 0.42)     
  **Medication use**                                                                                                    
  β-blockers                                                                                                            
   Yes                              11         0.87 (0.68 to 1.00)   10   0.60 (0.34 to 0.86)   0.27 (−0.05 to 0.59)    0.61
   No                               58         0.70 (0.56 to 0.84)   57   0.53 (0.38 to 0.68)   0.17 (−0.03 to 0.37)    
  ACE inhibitors                                                                                                        
   Yes                              14         0.75 (0.63 to 0.87)   6    0.48 (0.13 to 0.83)   0.27 (−0.10 to 0.64)    0.69
   No                               55         0.73 (0.55 to 0.91)   61   0.55 (0.41 to 0.69)   0.18 (−0.05 to 0.41)    
  ARBs                                                                                                                  
   Yes                              10         0.58 (0.41 to 0.75)   5    0.48 (0.24 to 0.72)   0.10 (−0.19 to 0.39)    0.55
   No                               59         0.78 (0.67 to 0.89)   62   0.56 (0.42 to 0.70)   0.22 (0.04 to 0.40)     
  Calcium channel blockers                                                                                              
   Yes                              7          0.70 (0.42 to 0.98)   8    0.40 (0.00 to 0.84)   0.30 (−0.21 to 0.81)    0.73
   No                               62         0.75 (0.60 to 0.90)   59   0.55 (0.41 to 0.69)   0.20 (0.00 to 0.40)     
  Statins                                                                                                               
   Yes                              12         0.80 (0.60 to 1.00)   12   0.46 (0.23 to 0.69)   0.34 (0.03 to 0.65)     0.19
   No                               59         0.74 (0.61 to 0.87)   56   0.65 (0.50 to 0.80)   0.09 (−0.11 to 0.29)    

\*N=number of patients with data available for variable and myocardial salvage index.

†Median difference=calculated median difference in myocardial salvage index between RIC and control groups using non-parametric quantile regression. CIs and p values for interaction are computed with non-parametric bootstrapping (1000 replications).

ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning.

When we tested for interaction, there was no significant difference in the efficacy of RIC in subgroups of cardiovascular risk factors, lipid and glucose levels, and medication use ([figure 2](#BMJOPEN2014006923F2){ref-type="fig"}).

![Stratum-specific median differences in MSI between RIC and control groups according to cardiovascular risk factors, lipid and glucose levels, and medication use. Median difference=calculated median difference in MSI between RIC and control groups using non-parametric quantile regression. CIs and p values for interaction are computed with non-parametric bootstrapping (1000 replications). ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; MSI, myocardial salvage index; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning.](bmjopen2014006923f02){#BMJOPEN2014006923F2}

Based on the point estimates, the effect of RIC tended to be reduced in smokers (median difference in MSI between RIC and control groups was −0.02 (95% CI −0.32 to 0.28) in smokers vs 0.25 (95% CI 0.08 to 0.42) in non-smokers, p value for interaction=0.13), although CIs were wide. In other subgroups of cardiovascular risk factors, there was no difference in the point estimates, such as ageing (median difference in MSI between RIC and control groups was 0.14 (95% CI −0.14 to 0.42) in patients ≥70 years vs 0.11 (95% CI −0.11 to 0.33) in patients \<70 years, p-value for interaction=0.87), gender (median difference in MSI between RIC and control groups was 0.33 (95% CI 0.01 to 0.65) in females vs 0.21 (95% CI −0.03 to 0.45) in males, p-value for interaction=0.56) and hypertension (median difference in MSI between RIC and control groups was 0.16 (95% CI −0.10 to 0.42) in patients with hypertension vs 0.12 (95% CI −0.15 to 0.39) in patients without hypertension, p-value for interaction=0.84).

Regarding medication use, point estimates indicated an increased effect of RIC in statin users (median difference in MSI between RIC and control groups was 0.34 (95% CI 0.03 to 0.65) in statin vs 0.09 (95% CI −0.11 to 0.29) in non-statin users, p value for interaction=0.19). No difference was seen in other subgroups of medication use, such as β-blocker treatment (median difference in MSI between RIC and control groups was 0.27 (95% CI −0.05 to 0.59) in β-blocker vs 0.17 (95% CI −0.03 to 0.37) in non-β-blocker users, p value for interaction=0.61).

Discussion {#s4}
==========

Our analysis did not demonstrate significant modification on the efficacy of RIC by cardiovascular risk factors and their medications in patients with STEMI undergoing pPCI. To our knowledge, this is the first investigation of a potential modification by cardiovascular risk factors and their medications on the efficacy of RIC as an adjunct to pPCI in a randomised controlled trial. Because the statistical power was limited, our study should be considered exploratory.

Cardiovascular risk factors {#s4a}
---------------------------

Although we did not find a significant modification by cardiovascular risk factors, our data indicated that the efficacy RIC might be reduced in smokers. The role of smoking in modulating cardioprotection by ischaemic conditioning strategies is unknown. The detrimental effects of smoking on the cardiovascular system, such as endothelial dysfunction, and activation of systemic inflammatory and prothrombotic processes, are mediated through a complex interaction of the several chemical compounds in tobacco smoke.[@R11] Our findings suggest that smoking disrupts some of the transduction pathways involved in RIC and this might be a subject for further investigation in experimental and clinical human studies.

Ageing may modify the efficacy of RIC.[@R5] The ageing heart is more susceptible to ischaemia-reperfusion injury through alternations in gene expression, signal transduction cascades and mitochondrial function.[@R12] In an experimental human study, the relative increase in flow-mediated vasodilation after RIC was higher in healthy elderly compared with young individuals.[@R13] Additionally, a recent animal study reported that RIC did not protect against ischaemia-reperfusion injury and even caused deleterious effects in isolated newborn rabbit hearts, but reduced infarct size in adult rabbit hearts.[@R14] Our intervention of four cycles with RIC seemed sufficient to preserve the cardioprotective effect of RIC also in elderly patients aged over 70 years.

Female hearts have an increased natural resistance to ischaemia-reperfusion injury, although it decreases with ageing.[@R5] Theoretically, this endogenous protection could restrict females from further exogenously activated cardioprotection by RIC. In our trial population of postmenopausal women, a cardioprotective effect of RIC seemed achievable. Our finding is supported by a meta-analysis of five randomised trials including 731 patients undergoing elective PCI, where the efficacy of RIC in reducing peri-procedural myocardial infarction did not vary according to female gender.[@R15]

The number of patients with diabetes mellitus was limited and our analysis does not allow a conclusion about the modification of the efficacy of RIC in patients with diabetes mellitus. In a randomised trial including 200 elderly patients with diabetes mellitus undergoing elective PCI, RIC failed to show a significant reduction in peri-procedural myocardial injury.[@R16] Two recent human and animal studies have shown the complexity of cardioprotection in diabetes mellitus. The first study demonstrated that the effect of RIC is dependent on preserved neural pathways in patients with diabetes mellitus.[@R17] The second study showed that while alterations in mitochondrial metabolism in type 2 diabetic rats are associated with protection against ischaemia-reperfusion injury at diabetes onset, detrimental effects occur in later stages of the disease.[@R18] Future large-scale human studies investigating the effect of RIC in patients with diabetes mellitus could improve our understanding by taking duration of diabetes mellitus and presence of diabetic neuropathy into account.

Until now, the interference of hypertension or LV hypertrophy with the ability to respond to RIC has only been examined in one animal study. Using a rat model of myocardial ischaemia, RIC seemed to protect myocardial contractile function in hypertrophied but surprisingly not normal rat hearts.[@R19] In a human study investigating the effect of RIC on flow-mediated vasodilation in the elderly, the relative increase in flow-mediated vasodilation after RIC was higher in the healthy elderly compared with elderly patients with hypertension.[@R13] Our subgroup analysis included very few patients with LV hypertrophy, but in patients with hypertension, the effect of RIC seemed preserved. However, it is important to note that we were unable to distinguish between patients with short-lasting and long-lasting hypertension.

Medication use {#s4b}
--------------

Little is known about the effect modification of statin use on RIC.[@R5] [@R6] Thus, we are the first to indicate a potential increased effect of RIC in statin users. Acute statin therapy seems to protect the myocardium directly from ischaemia-reperfusion injury, but the immediate cardioprotective effect may be attenuated in patients on persistent statin therapy.[@R20] Whether RIC has a more pronounced effect in statin users deserves further investigation.

The cardioprotective effect of long-term treatment with β-blockers is well documented.[@R23] However, it has been suggested that β-blocker use may interfere with other cardioprotective therapies.[@R5] We found that the efficacy of RIC seemed to also be preserved in β-blocker users. In contrast, a meta-analysis of 15 clinical trials, including 1155 patients randomised to treatment with or without RIC before cardiac surgery, showed an attenuated effect of RIC in patients on perioperative β-blocker treatment.[@R24]

Study limitations {#s4c}
-----------------

The predominant limitation of our study was the small sample size, resulting in low statistical power of the subgroup analysis to detect effect modification. Furthermore, the limited sample size did not allow multivariate analysis to control for residual confounding. Data on MSI were available only for the 56% of patients who met trial criteria. Lack of AAR evaluations was mainly responsible for missing MSI values, because SPECT was not available on a 24 h service basis. Between 72% and 85% of patients had lipid and glucose values measured, and only 65% of patients had echocardiographic M-mode measurements. However, because the missing data were assumed to be missing at random, systematic bias between treatment allocation and potential effect modifiers was unlikely. Another concern is that continuous variables were dichotomised using clinical cut-off points. Although dichotomising the variables introduced a potential risk of lost information, the sample size did not allow us to split continuous variables into more groups. Lipid concentrations undergo phasic changes during acute myocardial infarction. However, plasma lipids can be reliably assessed within 24 h after acute myocardial infarction as accomplished in our study.[@R25] Finally, we used LV mass calculated from day 1 echocardiographic measurements to determine the presence of LV hypertrophy. The risk of an overestimation of LV hypertrophy due to acute myocardial oedema may be present. To compensate, we defined LV hypertrophy as at least moderately elevated LV mass.

Conclusion {#s5}
==========

RIC as an adjunct to pPCI seems to improve MSI in our trial population of patients with STEMI regardless of most cardiovascular risk factors and their medications. Our post hoc finding on a limited sample size calls for further investigation in large-scale multicentre studies.
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